MIRA is advancing a focused pipeline of three oral programs across pain and metabolic diseases including clinical-stage Ketamir-2 and two programs advancing toward the clinic.
Oral NMDA receptor modulator designed for chemotherapy-induced peripheral neuropathy. Phase 1 completed with favorable safety and tolerability.
Phase
Ketamir-2
CIPN
Discovery
IND-Enabling
IND Cleared
Phase 1
P-1
Phase 2
P-2
Phase 3
P-3
Phase 2a protocol submitted under the active IND, with site initiation targeted for Q1 2027.*
*Target timing subject to site activation, IRB approval, and other customary study start-up requirements.
Phase
MIRA-55
Inflammatory Pain
Discovery
IND-Enabling
IND Cleared
Phase 1
P-1
Phase 2
P-2
Phase 3
P-3
Oral cannabinoid analog being developed as a safe approach to inflammatory pain, with preclinical research demonstrating analgesic activity comparable to morphine.
Advancing toward IND submission, targeted for 1H 2027.*
*Target timing subject to completion of IND-enabling activities, regulatory requirements, and other customary development factors.
Phase
SKNY-1
Obesity
Discovery
IND-Enabling
IND Cleared
Phase 1
P-1
Phase 2
P-2
Phase 3
P-3
Oral cannabinoid analog being developed for obesity, with preclinical research demonstrating weight reduction while preserving whole-body density.
Advancing toward IND submission, targeted for 1H 2027.*
*Target timing subject to completion of IND-enabling activities, regulatory requirements, and other customary development factors.
